Factors Affecting Adherence in a Pragmatic Trial of Annual Fecal Immunochemical Testing for Colorectal Cancer
- PMID: 30684199
- PMCID: PMC6544723
- DOI: 10.1007/s11606-018-4820-0
Factors Affecting Adherence in a Pragmatic Trial of Annual Fecal Immunochemical Testing for Colorectal Cancer
Abstract
Background: Colorectal cancer screening by fecal immunochemical test (FIT) reduces the burden of colorectal cancer. However, effectiveness relies on annual adherence, which presents challenges for clinic staff and patients.
Objective: Describe FIT return rates and identify factors associated with FIT adherence over 2 years in a mailed FIT outreach program in federally qualified health centers.
Design: Observational study nested in the Strategies and Opportunities to Stop Colon Cancer in Priority Populations (STOP CRC) trial. Five thousand one hundred ninety-five patients had an initial FIT order and were followed for ≥ 2 years (3574 also had a FIT order in the second year).
Main measures: FIT return percent in each year and patient- and neighborhood-level characteristics associated with FIT adherence.
Key results: Overall, the proportion of FIT orders that were completed was 46% in the patients' first year and 41% in the patients' second year. Of the 5195 patients with a FIT order in year 1, 3574 (69%) also had a FIT order in year 2 (71% of year 1 adherers and 67% of year 1 non-adherers, p = 0.009). Among those with a FIT order in the second year, the FIT return rate was about twice as high among those who were adherent in the first year (952/1674, or 57%) as among those who were not (531/1900, or 28%, p < 0.0001). Patient-level characteristics associated with higher odds of FIT return were a history of FIT screening at baseline, age over 65 (vs 50-65), no current tobacco use, recent receipt of a mammogram or flu vaccine, Asian ancestry (compared to non-Hispanic white), and non-English preference. The only neighborhood factor associated with lower FIT return rate was patient's larger residential city size.
Conclusion: Our findings can inform the customization of programs to promote FIT return among patients who receive care at federally qualified health centers.
Trial registration: http://www.clinicaltrials.gov.
Keywords: cancer; colorectal; fecal immunochemical test; screening.
Conflict of interest statement
Dr. Coronado served as a co-investigator on a study funded by Epigenomics and as a principal investigator on a study funded by Quidel Corporation. The studies had no influence on the design, conduct, or reporting of the present study. All remaining authors declare that they do not have a conflict of interest.
Figures
Similar articles
-
Effect of Reminding Patients to Complete Fecal Immunochemical Testing: A Comparative Effectiveness Study of Automated and Live Approaches.J Gen Intern Med. 2018 Jan;33(1):72-78. doi: 10.1007/s11606-017-4184-x. Epub 2017 Oct 10. J Gen Intern Med. 2018. PMID: 29019046 Free PMC article. Clinical Trial.
-
Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.JAMA Intern Med. 2013 Oct 14;173(18):1725-32. doi: 10.1001/jamainternmed.2013.9294. JAMA Intern Med. 2013. PMID: 23921906 Free PMC article. Clinical Trial.
-
Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial.JAMA Intern Med. 2018 Sep 1;178(9):1174-1181. doi: 10.1001/jamainternmed.2018.3629. JAMA Intern Med. 2018. PMID: 30083752 Free PMC article. Clinical Trial.
-
Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.JAMA. 2017 Sep 5;318(9):806-815. doi: 10.1001/jama.2017.11389. JAMA. 2017. PMID: 28873161 Free PMC article. Clinical Trial.
-
Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial.JAMA Intern Med. 2014 Aug;174(8):1235-41. doi: 10.1001/jamainternmed.2014.2352. JAMA Intern Med. 2014. PMID: 24934845 Clinical Trial.
Cited by
-
Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease.Crohns Colitis 360. 2021 Jun 16;3(3):otab028. doi: 10.1093/crocol/otab028. eCollection 2021 Jul. Crohns Colitis 360. 2021. PMID: 36776647 Free PMC article.
-
Data Challenges in Identifying Patients Due for Colorectal Cancer Screening in Rural Clinics.J Am Board Fam Med. 2023 Feb 8;36(1):118-129. doi: 10.3122/jabfm.2022.220216R1. J Am Board Fam Med. 2023. PMID: 36759133 Free PMC article.
-
Factors promoting breast, cervical and colorectal cancer screenings participation: A systematic review.Psychooncology. 2022 Sep;31(9):1435-1447. doi: 10.1002/pon.5997. Epub 2022 Jul 12. Psychooncology. 2022. PMID: 35793430 Free PMC article. Review.
-
Source matters: a survey of cost variation for fecal immunochemical tests in primary care.BMC Health Serv Res. 2022 Feb 15;22(1):204. doi: 10.1186/s12913-022-07576-4. BMC Health Serv Res. 2022. PMID: 35168616 Free PMC article.
-
What's the "secret sauce"? How implementation variation affects the success of colorectal cancer screening outreach.Implement Sci Commun. 2021 Jan 11;2(1):5. doi: 10.1186/s43058-020-00104-7. Implement Sci Commun. 2021. PMID: 33431063 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical

